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Abstract 
Aims/hypothesis The Coxsackie and adenovirus receptor (CAR) is a transmembrane cell-
adhesion protein that serves as an entry receptor for enteroviruses and may be essential for their 
ability to infect cells. Since enteroviral infection of beta-cells has been implicated as a factor 
that could contribute to the development of type 1 diabetes, it is often assumed that CAR is 
displayed on the surface of human beta cells. However, CAR exists as multiple isoforms and 
it is not known whether all isoforms subserve similar physiological functions. In the present 
study, we have determined the profile of CAR isoforms present in human beta cells and 
monitored the subcellular localisation of the principal isoform within the cells. 
Methods Formalin-fixed, paraffin-embedded pancreatic sections from non-diabetic individuals 
and those with type 1 diabetes were studied. Immunohistochemistry, confocal 
immunofluorescence, electron microscopy and western blotting with isoform-specific antisera 
were employed to examine the expression and cellular localisation of the five known CAR 
isoforms. Isoform-specific qRT-PCR and RNA sequencing (RNAseq) were performed on 
RNA extracted from isolated human islets. 
Results An isoform of CAR with a terminal SIV motif and a unique PDZ-binding domain was 
expressed at high levels in human beta cells at the protein level. A second isoform, CAR-TVV, 
was also present. Both forms were readily detected by qRT-PCR and RNAseq analysis in 
isolated human islets. Immunocytochemical studies indicated that CAR-SIV was the principal 
isoform in islets and was localised mainly within the cytoplasm of beta-cells, rather than at the 
plasma membrane. Within the cells it displayed a punctate pattern of immunolabelling, 
consistent with its retention within a specific membrane-bound compartment. Co-
immunofluorescence analysis revealed significant co-localisation of CAR-SIV with zinc 
transporter protein 8 (ZnT8), prohormone convertase 1/3 (PC1/3) and insulin, but not 
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proinsulin. This suggests that CAR-SIV may be resident mainly in the membranes of insulin 
secretory granules. Immunogold labelling and electron microscopic analysis confirmed that 
CAR-SIV was localised to dense-core (insulin) secretory granules in human islets, whereas no 
immunolabelling of the protein was detected on the secretory granules of adjacent exocrine 
cells. Importantly, CAR-SIV was also found to co-localise with protein interacting with C-
kinase 1 (PICK1), a protein recently demonstrated to play a role in insulin granule maturation 
and trafficking.    
Conclusions/interpretation: The SIV isoform of CAR is abundant in human beta cells and is 
localised mainly to insulin secretory granules, implying that it may be involved in granule 
trafficking and maturation. We propose that this subcellular localisation of CAR-SIV 
contributes to the unique sensitivity of human beta cells to enteroviral infection. 
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Research in context 
What is already known about this subject?  
• Human pancreatic beta cells are susceptible to infection by enteroviruses, including 
Coxsackievirus B, which use the Coxsackie and adenovirus receptor (CAR) as their 
entry receptor 
• CAR exists as at least five structurally distinct isoforms, which vary in their subcellular 
localisation and ability to mediate infection 
What is the key question?  
• Which CAR isoforms are expressed in the human pancreas?  
What are the new findings?  
• Human pancreatic beta cells principally express a specific isoform of CAR (CAR-SIV) 
that is localised to insulin secretory granules within the beta cells 
• CAR-SIV co-localises with protein interacting with C-kinase 1 (PICK1), a protein 
involved in insulin granule maturation and trafficking, suggesting a previously 
unrecognised role for CAR-SIV in this process 
• The localisation of CAR-SIV within the insulin secretory granules may contribute to 
the unique sensitivity of human beta cells to enteroviral infection 
How might this impact on clinical practice in the foreseeable future?  
• These studies suggest that CAR could be targeted selectively in beta cells as a means 
of minimising enteroviral infection and the development of islet autoimmunity 
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Introduction 
Epidemiological and pathological studies have linked enteroviral infections with the 
development of type 1 diabetes mellitus [1], but the mechanisms by which this might promote 
islet autoimmunity remain uncertain. One possibility is that islet cells are particularly sensitive 
to infection by enteroviruses and, in accord with this, enterovirus serotypes that are most often 
associated with type 1 diabetes (e.g. Coxsackievirus B [CVB]) have a clear tropism for human 
beta cells [2-4]. Additional support comes from evidence that enterovirus proteins are present 
in the beta cells of individuals with type 1 diabetes [5, 6] and that specific viral response 
pathways are activated in such cells [7, 8]. 
In order for enteroviruses to infect cells, they must bind to specific cell surface proteins that 
serve as vehicles to mediate their entry. Such binding is thought to alter the conformation of 
the viral capsid to facilitate the entry of viral RNA into the target cell. An endogenous cellular 
protein known as the Coxsackie and adenovirus receptor (CAR) is one such viral receptor. 
CAR is a transmembrane protein involved in homotypic cell adhesion and tight junctional 
integrity [9] but also serves as a primary cellular attachment protein for CVBs and adenoviruses 
[10], presumably in a subversion of its normal physiological role.  
Full-length CAR is encoded by the CXADR gene, which comprises eight exons and yields a 
protein with an extracellular domain (ECD) linked by a single transmembrane region to a 
cytoplasmic tail. Differential splicing yields at least five different isoforms (Fig. 1a,b), but only 
two of these contain the transmembrane domain and are likely to be retained within cells. 
Structural studies have suggested that enteroviruses bind to the D1 domain in the extracellular 
region of the protein [11, 12] and, accordingly, four of the isoforms (designated CAR-SIV, 
CAR-TVV, CAR4/7 and CAR3/7) have been shown to bind enterovirus. However, only CAR-
SIV and CAR-TVV retain the transmembrane domain and are thus able to mediate a productive 
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infection in cells. The two soluble isoforms are released from cells and may protect from 
infection by sequestering active virus in the extracellular fluid [11].  
Interestingly, the two isoforms bearing a transmembrane domain vary only in the sequence of 
the final 26 (CAR-SIV) or 13 (CAR-TVV) amino acids, but are differentially localised within 
cells and may fulfil different functions [13]. The CAR-SIV isoform (also known as 
CAREx7[13]) is encoded by the first seven exons of the human CXADR gene and is expressed 
preferentially on the basolateral surface of polarised cells. In contrast, the C-terminal region of 
the CAR-TVV isoform (also known as CAREx8) is produced from a cryptic splice site within 
the seventh exon linked to exon 8, and is expressed apically [13]. The C-terminal region 
encodes a consensus PDZ-binding domain whose amino acid sequence varies between the 
CAR-SIV and the CAR-TVV forms, which probably accounts for the differential localisation 
of the two variants within polarised cells [13-16]. In support of this, both the SIV and TVV 
forms of CAR can interact with proteins such as membrane-associated guanylate kinase, WW 
and PDZ domain-containing protein 1b (MAGI-Ib), postsynaptic density protein 95 (PSD-95) 
[13, 15, 16] and zonula occludens-1 (ZO-1) [14], but only the CAR-SIV isoform interacts with 
protein interacting with C-kinase 1 (PICK1) [13]. Strikingly, PICK1 is abundantly expressed 
in beta cells and has recently been shown to control insulin granule trafficking. Indeed, loss of 
PICK1 results in impaired glucose tolerance and reduced serum insulin concentrations in 
experimental animals [17, 18]. Thus, an interaction between PICK1 and the SIV isoform of 
CAR in beta cells could be of functional importance.  
To date, few studies have examined the expression and distribution of CAR isoforms in human 
beta cells [3, 19]. Ylipaasto et al [3] confirmed a role for CAR by demonstrating that pre-
treatment of isolated human islets with a blocking antibody (clone RmcB) protected the cells 
from CVB infection [3]. More recently, CAR expression was confirmed in human pancreas, 
albeit using an antiserum that does not discriminate between the various isoforms [20]. We 
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have thus characterised and mapped the expression and distribution of CAR isoforms in human 
pancreas. 
 
Methods  
Tissue and cell lines Formalin-fixed, paraffin–embedded (FFPE) pancreatic sections from the 
Exeter Archival Diabetes Biobank (http://foulis.vub.ac.be/) and from the Network for 
Pancreatic Organ donors with Diabetes (nPOD) (Florida, USA) were studied. Samples were 
from 21 non-diabetic individuals (age range 4-47 years) and ten individuals with type 1 
diabetes (age range 6-47 years; see electronic supplementary material [ESM] Table 1). Isolated 
human islets were obtained from the Oxford Centre for Islet Transplantation (Oxford, UK) or 
purchased from Lonza (Basel, Switzerland). On arrival, islets were cultured for 24h at 37°C 
and then fixed and processed for immunostaining by standard immunofluorescence (FFPE) 
techniques, or stored at −80oC for RNA extraction. Ethics approval (West of Scotland Research 
Committee 4 (WoSREC4); 15/WS/0258) was gained for all the samples studied. The pancreatic 
tissue samples from the Exeter Archival Diabetes Biobank and nPOD were selected based on 
age of demise, and in the case of Type 1 diabetes, duration of disease; tissue quality; sample 
availability (which is restricted within these biobanks) and appropriateness of tissue for IHC/ 
IF approaches. Samples with extensive autolysis or evidence of other unrelated pancreatic 
diseases were excluded.  Blinding of donor type and immunofluorescence stain was performed 
for the co-localisation studies. The human beta cell lines EndoC-βH1 and 1.1B4s were cultured 
as described in ESM Methods.  
 
Antibodies Three different anti-CAR sera were employed (ESM Table 2) based on their 
selective immunoreactivity against the C-terminus (CAR-CT) or regions within the ECD 
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(CAR-ECD and CAR-RmcB) of the protein, respectively, and validated as described below 
and in ESM Fig. 1. These allowed the various isoforms of CAR to be distinguished, as 
illustrated in Fig. 1b. All other antisera are described in ESM Table 2.  
 
Mutagenesis Site-directed mutagenesis was performed to remove the final three amino acids 
(SIV) of CAR-SIV to examine the specificity of the CAR-CT antiserum (ESM Methods).  
 
Western blotting The production of CAR in human islets and EndoC-βH1 cells and the 
specificity of the CAR-CT and CAR-RmcB antisera were assessed using western blotting 
(ESM Methods). 
 
Flow cytometry The specificity of the CAR-CT and CAR-RmcB antisera was assessed using 
flow cytometry (ESM Methods). 
 
Immunohistochemistry This was performed using a standard immunoperoxidase approach 
[21]. Bright-field image acquisition was performed using a Nikon 50i Microscope fitted with 
a DS-Fi camera and a DSL2 camera control unit (Nikon, Kingston Upon Thames, UK). 
Antibody details and conditions are described in ESM Table 2.  
 
Immunofluorescence (FFPE) To examine multiple antigens within the same section, samples 
were probed in a sequential manner with up to three different antibodies (ESM Table 2) [22]. 
Pancreas sections were initially subjected to heat-induced epitope retrieval in 10mmol/l citrate 
buffer (pH 6), and relevant antigen–antibody complexes were detected using secondary 
antibodies conjugated with fluorescent dyes (Alexa Fluor anti-mouse 488, anti-rabbit 555, and 
anti-guinea pig 568 or 647; Invitrogen, Paisley, UK). Cell nuclei were stained with DAPI. After 
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mounting, images were captured either with a Leica AF6000 microscope (Leica, Milton 
Keynes, UK), then were processed using the standard LAS X Leica software platform (Version 
3.3.0.16799), or with a Leica SP8 confocal microscope and Hyvolution2 deconvolution 
software (Scientific Volume Imaging, Hilversum, The Netherlands). Co-localisation analysis 
was undertaken with a JACoP plugin from Image J, version 1.48 Java 1.6.0 _20 
(https://imagej.nih.gov/ij/plugins/track/jacop2.html). 
 
 
Quantitative RT-PCR (qRT-PCR)/semi-quantitative RT-PCR The relative expression 
levels of the CAR-SIV, CAR-TVV, CAR4/7, CAR3/7 and CAR2/7 isoforms in isolated human 
islets and laser capture microdissected (LCM) islets were determined using qRT-PCR (ESM 
Methods).  
 
RNAseq RNA sequencing (RNAseq) was performed using islets obtained from 
normoglycaemic human islet donors or EndoC-βH1 cells as previously described [23]. Genes 
and transcripts were assigned a relative coverage rate as measured in reads per kilobase of exon 
model per million mapped reads and compared with 15 other normal human tissues, analysed 
by RNAseq and deposited at the Illumina BodyMap 2.0 dataset (GEO accession number 
GSE30611), accessed on August 9, 2017. 
 
Cryoimmune electron microscopy We used cryoimmune electron microscopy to assess and 
quantify the localisation of CAR-SIV, zinc transporter protein 8 (ZnT8), insulin and proinsulin 
in human pancreas samples as described previously [24] and in the ESM Methods. 
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Co-immunoprecipitation of PICK1 with CAR This was performed in EndoC-βH1 cells and 
human islets as described in ESM Methods.  
 
Statistical analysis Immunofluorescence images of islets were selected randomly from stained 
pancreas sections. The Pearson correlation coefficient was used to estimate the co-localisation 
between proteins using the JACoP plugin from Image J. Values for the Pearson correlation 
coefficient ranged from 0 for no correlation, to 1 for a positive correlation. GraphPad Prism 
5.04 (La Jolla, California, USA) was employed for all statistical analysis, and data are 
expressed as means ±SEM. Statistical significance was calculated using one-way ANOVA, 
and the Bonferroni multiple comparison test was used  for multiple comparisons. A p value 
<0.05 was considered statistically significant. 
 
Results 
Differential CAR immunostaining in human pancreas The availability of antisera directed 
against different regions of the CAR protein (Fig. 1b) enabled the expression profiles of the 
two isoforms bearing a transmembrane domain to be studied. The antiserum designated CAR-
CT was raised against a peptide containing the C-terminal 35 amino acids of the CAR-SIV 
protein and required the presence of the triplet ‘’SIV’ sequence at the immediate C-terminus 
for immunoreactivity. As such, it did not label any other isoform of CAR. This specificity was 
confirmed by transfection of 1.1B4 cells with constructs encoding either the full-length CAR-
SIV or a variant in which the final three amino acids (SIV) had been removed by targeted 
mutagenesis (ESM Methods). Western blotting and immunofluorescence staining confirmed 
immunorecognition of the full-length CAR-SIV isoform, but not the truncated form, by the 
CAR-CT antiserum (ESM Fig. 1).  
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Two further CAR antibodies, CAR-ECD (Abcam, Cambridge, UK) and RmcB (Merck 
Millipore, Watford, UK), both of which recognise the ECD of human CAR, were also used. 
By deploying a panel of approaches (western blotting, immunofluorescence staining of fixed 
cells, flow cytometry and immunohistochemistry in FFPE sections), it was found that the CAR-
ECD antiserum worked effectively in both western blotting and immunohistochemistry, 
whereas the RmcB clone was most suitable for immunofluorescence staining of fixed cells or 
flow cytometry. As noted above, both the CAR-ECD and RmcB antibodies recognise multiple 
isoforms of CAR including CAR-SIV, CAR-TVV and CAR4/7 (ESM Fig. 1b,c). 
Use of these differentially specific antisera revealed that various isoforms of CAR are 
expressed differentially among the exocrine and endocrine compartments of the human 
pancreas (Fig. 1c,d). Importantly, the CAR-CT antiserum labelled only islet cells (Fig. 1c) 
whereas use of the CAR-ECD antiserum resulted in labelling of both exocrine and endocrine 
tissue (Fig. 1d). An identical staining pattern was confirmed in a total of eight pancreases from 
non-diabetic donors (within the Exeter and nPOD Biobanks), ranging in age from 4 weeks to 
59 years of age (ESM Table 1).  
 
Confirmation of SIV isoform expression by qRT-PCR in human islets Isoform-specific 
primers were used to analyse CXADR isoform expression (ESM Table 3) by qRT-PCR in RNA 
extracted from isolated human islets (ESM Table 4). This revealed that transcripts encoding 
the CAR-SIV and CAR-TVV isoforms were expressed at the highest levels, while the soluble 
CAR4/7 isoform was less abundant (Fig. 2a). The two shorter isoforms CAR3/7 and CAR2/7 
were barely detectable. These results were confirmed in a second set of independent samples 
in which RNA was isolated from LCM islets (Fig. 2b; ESM Table 5). This was further 
confirmed by RNAseq analysis of isolated human islets (Fig. 2c). Importantly, CAR-SIV was 
enriched threefold compared with CAR-TVV in the human pancreatic beta cell line EndoC-
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βH1 (ESM Fig. 2a; ESM Methods) [25], and semi-quantitative RT-PCR analysis of RNA 
extracted from two highly purified preparations of human islets revealed that the expression of 
CAR-SIV was greater than that of CAR-TVV (ESM Fig. 2b). Finally, the presence of the SIV 
isoform was verified by western blotting in isolated human islets and EndoC-βH1 cell using 
the CAR-CT and CAR-ECD antisera (Fig. 2d). 
 
The SIV isoform is expressed preferentially in human beta cells To determine whether the 
SIV isoform of CAR is preferentially localised to a specific endocrine cell subset, combined 
immunofluorescence staining using anti-CAR-CT, insulin and glucagon was performed. This 
revealed that expression of the CAR-SIV isoform was restricted solely to beta cells in human 
pancreas sections (Fig. 3a) and isolated human islets (Fig. 3b). Somewhat surprisingly, rather 
than being localised to the cell surface, the CAR-SIV isoform was distributed mainly within 
the cytoplasm of beta cells. Confocal microscopy revealed that CAR-SIV displayed a punctate 
distribution and that it specifically co-localised with insulin, suggesting a possible association 
with secretory granules (Fig. 3c). A similar pattern of punctate immuno-co-localisation with 
insulin was observed when using an alternative CAR antiserum (CAR-ECD; data not shown).  
To explore these relationships further, the expression of CAR-SIV was investigated in the 
pancreases of a series of people with type 1 diabetes (ten individuals; 3-42 years of age; ESM 
Table 1, ESM Fig. 3) and islet autoantibody-positive non-diabetic individuals (two participants, 
aged 18 and 37 years, respectively). The samples from individuals with type 1 diabetes 
contained both insulin-deficient islets and insulin-containing islets. CAR-SIV expression was 
absent from the insulin-deficient islets, but was clearly visible in residual insulin-containing 
islets. Neither the subcellular distribution nor the staining intensity differed between the type 
1 diabetic, autoantibody-positive non-diabetic and non-diabetic islets (ESM Fig. 3 and data not 
shown). Finally, by applying the CAR-CT antibody to a human tissue microarray (gift from 
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Alan Foulis; University of Glasgow, UK), it was confirmed that the SIV isoform could be 
variously found at the surface membrane (testes and bladder small cell carcinoma) and/or in 
cytoplasmic regions (stomach and islets) within normal and cancerous tissues (ESM Fig. 4). 
RNAseq data supported this expression profile (ESM Fig. 4).  
 
CAR-SIV co-localises with secretory granule proteins in beta cells In order to verify the 
localisation of CAR-SIV in beta cells, confocal co-immunofluorescence studies were 
performed to localise certain other proteins (ZnT8, Fig 4a; prohormone convertase 1/3 [PC1/3], 
Fig 4b; and proinsulin, Fig 4c) known to be present in secretory granules. Calculation of the 
Pearson correlation coefficient confirmed that insulin strongly associated with ZnT8 
(0.94±0.01; Fig. 4d). Importantly, CAR-SIV also correlated strongly with insulin (0.95±0.02; 
Fig. 4d) and PC1/3 (0.81±0.02; Fig. 4d). In contrast, CAR-SIV did not associate with glucagon 
(0.05±0.02; Fig. 4d,e) and was more weakly associated with proinsulin (0.55±0.04; Fig 4d). 
High-resolution confocal microscopy confirmed the co-localisation of CAR-SIV with ZnT8 
(Fig. 4f) and PC1/3 (Fig. 4g), and showed that CAR-SIV and proinsulin were less frequently 
co-localised (Fig. 4h). Using a more sophisticated reciprocal analysis, it was confirmed that the 
majority of CAR-SIV co-localised with insulin (Manders co-localisation coefficient [MCC] 
0.914±0.016) and that this was also true in reverse (i.e. the proportion of insulin co-localising 
with CAR-SIV was high (MCC 0.912±0.028; ESM Fig. 5).  
By contrast, although a large proportion of total proinsulin co-localised with CAR-SIV (MCC 
0.708±0.082), this did not hold in reverse (CAR-SIV:proinsulin, MCC 0.211±0.042) because 
little proinsulin escaped into mature secretory granules. Together, these findings suggest that 
CAR-SIV is present in both immature and mature insulin secretory granules in human beta 
cells. 
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Cryoimmune electron microscopy confirms that CAR-SIV is localised to insulin secretory 
granules To confirm more directly that the CAR-SIV isoform localises to insulin secretory 
granules, immunogold labelling was performed on thin frozen sections using the post-
embedding Tokuyasu method [24] with antisera against CAR-SIV (10 nm gold particles) and 
ZnT8 (5 nm gold particles). This revealed that both antisera localise to secretory granules in 
human pancreas sections (Fig. 5); the characteristic electron-dense appearance of the granule 
cores implies that they contain insulin. This was verified by immunostaining with anti-insulin 
(ESM Fig. 6). By contrast, gold particles were not concentrated in the secretory granules of 
exocrine cells. Immunogold labelling of insulin secretory granules with the CAR-CT antibody 
demonstrated that localisation was least abundant in the centre of the granule cores and 
preferentially displayed at their periphery (Fig. 5c,d). Labelling of ZnT8 showed a similar 
distribution.  
Quantification of 841 CAR-SIV immunogold particles from 21 different micrographs, across 
1291 different membrane intersections, revealed that CAR-SIV was most abundant on mature 
insulin secretory granules (79%). CAR-SIV was also observed in immature insulin granules 
(14.4%), but was rarely observed in beta cell nuclei (2.5%), mitochondria (1.0%) or 
endoplasmic reticulum (1.1%) or on the plasma membrane (1.2%; Fig. 5b,e). Of note, uranyl 
acetate yields a ‘negative contrast’ for organelle membranes in the staining method employed, 
and as a consequence the appearance of the secretory granules differs from that seen with 
osmium labelling.  
To further confirm the presence of CAR-SIV in the insulin granules at different stages of 
granule maturation, immunogold labelling of normal pancreas sections to detect proinsulin (20 
nm gold particles), CAR-SIV (10 nm gold particles) and insulin (5 nm gold particles) was 
performed (ESM Fig 6). This revealed the presence of CAR-SIV in immature granules, defined 
as proinsulin and CAR-SIV positive (ESM Fig. 6c); maturing granules, defined as proinsulin, 
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insulin and CAR-SIV positive (ESM Fig. 6d); and mature granules, defined as insulin and 
CAR-SIV positive (ESM Fig. 6e). Examination of 122 granules containing CAR-SIV revealed 
that six (4.9%) were also positive for proinsulin (immature granules); 30 (24.6%) were also 
positive for proinsulin and insulin (maturing granules), and the majority 86 (70.5%) were 
positive for insulin (mature granules). Taken together, these results suggest that CAR-SIV is 
present within the granule membrane at all stages of granule maturation. 
 
CAR-SIV co-localises with PICK1 in insulin secretory granules PICK1 may play an 
important role in insulin granule trafficking and maturation [18], and the SIV isoform of CAR, 
but not the TVV isoform, selectively interacts with PICK1 in other cell types [13, 15]. To assess 
whether CAR-SIV co-localises with PICK1 in human beta cells, further confocal co-
immunofluorescence studies (Fig. 6) and immunoprecipitation (ESM Fig. 7) studies were 
performed. PICK1 was readily detected in islet endocrine cells (in both beta and non-beta cells; 
Fig. 6a) and, importantly, it co-localised with CAR-SIV in beta cells (Fig. 6a) and was co-
immunoprecipitated with CAR from EndoC-βH1 cells and human islets (ESM Fig. 7). 
Pearson’s correlation analysis of the immunofluorescence signals (Fig. 6b) confirmed a strong 
association between PICK1 and both CAR-SIV (0.73±0.02) and insulin (0.84±0.04). 
To examine the co-localisation of PICK1, CAR-SIV and insulin in more detail, confocal 
microscopy coupled with Hyvolution software was employed to provide improved resolution. 
This confirmed the intimate association between PICK1 and the SIV isoform of CAR within 
insulin secretory granules (Fig. 6c). PICK1 was also observed in association with the secretory 
granules of other islet non-beta endocrine cells, but CAR-SIV was not detected in those cells 
(Fig. 6).  
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Discussion 
The present study reveals that the SIV isoform of CAR is expressed selectively by beta cells in 
the human pancreas. This finding was confirmed at both the RNA and protein levels. We also 
discovered that the subcellular localisation of CAR-SIV was atypical: the protein was found 
mainly within the cytoplasmic domain of beta cells rather than at the cell surface.  
We used both immunological and molecular biological approaches to investigate CAR 
expression in human islet cells, and the results were concordant. Thus, analysis of RNA 
extracted either from isolated human islets or laser capture microdissected islets revealed that 
two major isoforms of CAR, CAR-SIV and CAR-TVV, were present. Both of these contain a 
single transmembrane domain, implying that they could each be localised within defined, 
membrane-limited, compartments in the islet cells, as in other cell types [13]. The results 
favoured a preponderance of the CAR-SIV isoform in islets, and immunohistochemical 
analysis confirmed abundant production of CAR-SIV protein in human islet cells, contrasting 
with its absence from the exocrine pancreas. Taken as a whole, the results suggest that the 
major isoform of CAR present in human islets is CAR-SIV, although CAR-TVV is also 
present. CAR-SIV is expressed preferentially in beta cells, since we were unable to find 
evidence for its expression in ‘non-beta’ islet cells. By contrast, use of less selective antisera 
suggested that additional isoforms of CAR (including CAR-TVV) may be present among the 
other non-beta endocrine cells. This would be consistent with the analysis of RNA expression. 
The primary subcellular localisation of CAR in beta cells has not been extensively addressed 
in previous work [3, 20] but, despite this, in other cell types a consensus has emerged that this 
protein is often localised within tight junctional complexes at the plasma membrane [13, 14, 
26]. As such, CAR would be expected to be present at the cell surface, where it could fulfil a 
secondary (presumably subverted) role as a vehicle for viral entry. Thus, the present 
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demonstration that CAR-SIV is present in human beta cells is consistent with the known 
sensitivity of these cells to infection by various enterovirus serotypes. However, the intriguing 
discovery that this isoform was localised primarily at an intracellular site in beta cells suggests 
a more complex scenario (and a different physiological role) compared with other cells in 
which CAR resides mainly on the plasma membrane.  
High-resolution confocal microscopic analysis was used to examine in more detail the 
unexpected subcellular localisation of CAR-SIV in beta cells. This revealed a punctate, 
cytoplasmic immunolabelling pattern for CAR-SIV, consistent with its distribution in a distinct 
intracellular organelle compartment. Additional studies demonstrated that this 
immunolabelling profile correlated with that of insulin, as well as with two additional secretory 
granule proteins, ZnT8 and PC1/3, thereby implying a localisation within beta cell insulin 
secretory granules. Direct confirmation of this was provided by cryoimmune electron 
microscopy studies in which immunogold methods allowed the visualisation of CAR-SIV, 
principally in association with the dense-core granules characteristically found in beta cells. 
By contrast, no labelling was seen in the equivalent secretory granules found in adjacent 
exocrine cells, implying that CAR-SIV is not absolutely required for secretory granule 
biogenesis in all cell types.  
Importantly, and consistent with results obtained in other cells [18], we also noted that CAR-
SIV co-localised with, and could be immunoprecipitated with, the PDZ domain protein PICK1 
in beta cells. PICK1 plays a specific role in insulin secretory granule maturation [18, 27], and 
it is conceivable that CAR-SIV serves as a selective binding partner for PICK1 in beta cells, 
thereby concentrating the two proteins within maturing secretory granules. Consistent with this 
hypothesis, we found by immunofluorescence analysisat the SIV isoform of CAR is much more 
strongly associated with mature insulin than with proinsulin, suggesting that CAR (and PICK1) 
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may become concentrated in secretory granules as these mature beyond their emergence from 
the trans-Golgi network.  
If this model is correct, it has additional important consequences. In particular, the model 
predicts that the C-terminus of CAR-SIV must face the extragranular environment, since its 
PDZ-binding domain is located in this region and would only be available to interact with 
cytoplasmic PICK1 (or other cytoplasmic PDZ-binding proteins) in this orientation. As such, 
the putative ECD of CAR-SIV would then face the lumen of the granule, with the single 
transmembrane region serving to anchor the protein in this orientation in the limiting membrane 
surrounding the granule. Thus, the region of SIV required for the binding of enteroviruses 
would face the interior of the secretory granule during maturation. It follows from this that the 
ECD of CAR-SIV would become displayed on the external face of the plasma membrane 
following the fusion of the secretory granule and plasma membranes during exocytosis. 
These considerations are summarised in Fig. 7 and suggest that enteroviral entry into beta cells 
may be facilitated under conditions in which the rate of secretory granule exocytosis is high 
(and granule membrane recycling rates are correspondingly elevated). Thus, CAR-SIV appears 
to be configured in beta cells such that it can interact with PDZ-binding proteins during 
secretory granule maturation, and its virus-binding domain becomes exposed to the 
extracellular environment during exocytosis. Of note, most of the autoantigens in type 1 
diabetes are expressed in the insulin granule [28] and the preferential localisation of viral 
receptors in the granule indicates a potential mechanism by which CVB infection may modify 
the processing of granule proteins, to promote the generation of autoantigens. 
In support of our conclusions, Ylipaasto et al [3] demonstrated that the pre-treatment of human 
islets with a blocking antibody directed solely against externally oriented CAR attenuated 
infection with Coxsackie viruses. When coupled with our finding that the majority of CAR is 
located intracellularly in islet cells, this suggests that externalisation of the protein occurs to 
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mediate viral entry. Moreover, we also note Hodik et al’s [29] demonstration that enterovirus 
replication complexes and viral particle lattices are present on or near to insulin granules in 
CVB acutely infected beta cells. Thus, this weight of evidence is strongly supportive of our 
hypothesis and deserves further study. 
In summary, we show that human beta cells express the SIV isoform of CAR in the insulin 
granules. We propose that the biochemical properties of CAR-SIV that confer the physiological 
importance of this protein within beta cells may also represent an ‘Achilles heel’ by which the 
entry and replication of enteroviruses is facilitated.  
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Figure Legends 
Fig. 1 A description of the CAR isoforms and the selective expression of CAR-SIV in human 
islets. (a) CAR protein structure. The signal peptide (red) is cleaved to yield a mature protein 
with an ECD comprising two immunoglobulin (Ig)-like domains, type 1 (blue) and type 2 
(green). The transmembrane domain (yellow) bridges the extracellular and cytoplasmic regions 
(pink), which terminates with a PDZ-binding domain (red). (b) CXADR exon maps of the five 
differentially spliced isoforms. The type 1 Ig domain is encoded by exons 2 and 3, while type 
2 Ig-like domain is encoded by exons 4 and 5. Isoforms 1 and 2 contain a transmembrane 
domain and are named CAR-SIV (or hCAR1, CAREx7) and CAR-TVV (or hCAR2, CAREx8), 
respectively (denoted by the three terminal amino acids on their C-termini). The soluble 
isoforms 3, 4 and 5 are named CAR4/7, CAR3/7 and CAR2/7, respectively, reflecting exon 
inclusion or exclusion and lack of the transmembrane domain. The binding regions of the 
different CAR antibodies are also shown. The CAR-CT antiserum recognises amino acids 335–
365 located at the C-terminus of the CAR-SIV isoform but does not recognise the other CAR 
isoforms. Both the CAR-ECD and CAR-RmcB antisera recognise epitopes within the ECD, 
and are predicted to recognise the majority of the longer CAR isoforms (CAR-SIV, CAR-TVV, 
CAR4/7 and potentially CAR3/7). (c, d) Representative immunocytochemical analysis of the 
expression of different CAR isoforms in normal control pancreas tissue stained with (c) CAR-
CT and (d) CAR-ECD antisera. Scale bars, 20 µm. The insets below represent higher 
magnification images (of the areas outlined by the black boxes) demonstrating the differential 
staining profile of the CAR-CT antisera in the endocrine (+++) and  exocrine pancreas (−), and 
the CAR-ECD antisera in the endocrine (+++) and exocrine pancreas (+);  +++, strong; +, 
weak; –, negative. These results are representative of findings in pancreas from eight non-
diabetic individuals; aa, amino acids, Ab., antibody 
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Fig. 2 Confirmation of SIV isoform expression in human islets. qRT-PCR analysis of CXADR 
isoform expression in (a) isolated human islets (n=5 individuals) and (b) LCM human islets 
(n=2 individuals) demonstrates that the SIV and TVV isoforms are highly expressed, CAR4/7 
is present at low levels, and CAR3/7 and CAR2/7 are barely detectable. Data were normalised 
to the relative expression of three housekeeping genes β-actin, GAPDH and B2M. Relative 
expression is presented as the mean ± SEM. (c) RNAseq data showing CAR isoform expression 
in islets from five normoglycaemic individuals (mean ± SEM) [23]. RPKM, reads per kilobase 
of exon model per million mapped reads. (d) Confirmation of CAR-SIV protein expression in 
isolated human islets and EndoC-βH1 cells as assessed by western blotting using CAR-CT and 
CAR-ECD antisera and loading control GAPDH. H., human 
Fig. 3 The SIV isoform of CAR is expressed in pancreatic beta cells. (a) Representative 
immunofluorescence staining of the CAR-SIV isoform (CAR-CT antibody; green), insulin 
(light blue), glucagon (red) and DAPI (dark blue) in an islet from a non-diabetic human 
pancreas. Scale bars, 10 µm. (b) CAR-SIV isoform staining in formalin-fixed, paraffin-
embedded isolated human islets: CAR-SIV (CAR-CT; green) and insulin (red) and DAPI (dark 
blue). The enlarged region (from the area outlined by the dashed white box) demonstrates co-
localisation of CAR-CT and insulin staining (yellow). Scale bars, 10 µm. (c) Granular 
distribution of CAR-SIV (green) and co-localisation with insulin (red) and DAPI (dark blue) 
in the islet of a non-diabetic pancreas. Scale bars, 5 µm. These results are representative of 
findings in the pancreases of 15 non-diabetic individuals (ESM Table 1) 
Fig. 4 CAR-SIV co-localisation with multiple insulin granule proteins within the beta cell. 
Representative immunofluorescence staining of the CAR-SIV isoform (CAR-CT antibody; 
green) and insulin (blue) in relation to insulin secretory granule proteins (red) (a) ZnT8, (b) 
PC1/3 and (c) proinsulin. (d) Pearson correlation coefficient demonstrating the association 
between CAR-SIV and glucagon, insulin, ZnT8, PC1/3 and proinsulin, and between ZnT8 and 
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insulin. Each data point represents a single islet, and two islets were assessed per case from 
each of three independent samples. Representative higher magnification images of the CAR-
SIV isoform (CAR-CT antibody; green) with (e) glucagon, (f) ZnT8, (g) PC1/3 and (h) 
proinsulin in red. DAPI is shown in dark blue. No association was observed between the CAR-
SIV isoform (CAR-CT antibody; green) and glucagon (red) (e). Scale, bars 10 µm 
Fig. 5 Cryoimmune electron microscopy. Immunogold labelling of CAR-SIV (10 nm gold 
particles) and ZnT8 (5 nm gold particles) in thin frozen sections of human pancreas tissue. (a) 
The low-magnification image demonstrates the presence of granules in acinar cells and in islet 
cells. (b, c) The higher magnification images (of the areas outlined by the dashed black boxes 
in a) reveal a lack of CAR-SIV labelling of acinar cell granules (b), but positive CAR-SIV 
labelling in beta cell granules (c). (d) A higher resolution, magnified image confirms that the 
labelling of CAR-SIV (10 nm gold; black arrows) and ZnT8 (5 nm gold; black arrowheads) 
surrounds the beta cell granules. Scale bars, 2 µm (a), 1 µm (b, c), and 500 nm (d). (e) Relative 
distribution of CAR-SIV in organelles based on quantification using line intersection counting. 
ER, endoplasmic reticulum 
Fig. 6 CAR-SIV co-localisation with PICK1 in the beta cell. (a) Representative 
immunofluorescence staining of PICK1 (red), CAR-SIV isoform (CAR-CT antibody; green), 
insulin (light blue) and DAPI (dark blue) in non-diabetic human pancreas. Overlay of CAR-
SIV and PICK1 (yellow), and CAR-SIV, PICK1 and insulin (white). (b) Pearson correlation 
coefficient demonstrating the extent of co-localisation of CAR-SIV with PICK1, CAR-SIV 
with insulin, and PICK1 with insulin. (c) Hyvolution imaging demonstrates a close association 
of the CAR-SIV isoform (CAR-CT antibody; green) and PICK1 (red) in the insulin granule 
(light blue) of a non-diabetic pancreas. Granules positive for insulin, PICK1 and CAR-SIV are 
indicated by the orange arrows. Scale bar, 5 µm 
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Fig. 7 CAR-SIV in beta cells. Our data demonstrate that CAR-SIV is present at high 
concentrations on the insulin granule and is closely associated with the cytoplasmic protein 
PICK1. CAR-SIV has previously been shown to interact with PICK1, which is proposed to 
have a role in the budding and maturation of vesicles from the trans-Golgi network. We predict 
that the C-terminus of CAR-SIV faces the extragranular/cytoplasmic environment since its 
PDZ-binding domain would be available to interact with cytoplasmic PICK1 only in this 
orientation. We propose that CAR-SIV, through its interaction with PICK1, could therefore 
play a hitherto unsuspected role in the maturation and trafficking of the insulin granule. 
Importantly, when considering the orientation of CAR-SIV in this model, the putative ECD of 
CAR-SIV, which is required for the binding of enteroviruses, faces the interior of the secretory 
granule during its maturation. This suggests that, as the insulin granule fuses with the plasma 
membrane during insulin exocytosis, the ECD of CAR-SIV becomes displayed on the external 
face of the plasma membrane and is then able to bind to enteroviruses that use this receptor, 
for example CVBs. During the subsequent endocytosis of the granule, for recycling, the virus 
would be transported inside the cell, where it could initiate a productive infection 
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 ESM METHODS: 
Cell culture  
The human beta cell line EndoC-βH1 (kindly provided by Dr. R. Scharfmann, University of 
Paris, France (1) was cultured in Matrigel-fibronectin-coated plates as described (2). Cells were 
cultured in DMEM containing 5.5mmol/l glucose, 2% bovine serum albumin (fraction V), 
50µmol/l β-mercaptoethanol, 5.5µg/ml transferrin, 6.7ng/ml sodium selenite, 10mM 
nicotinamide, penicillin (100units/ml) and streptomycin (100µg/ml). Cells were seeded at 1.75 
x106/ml on an extracellular matrix (ECM) with fibronectin coated T25 flasks and were sub-
cultured every 7-9 days. Half of the culture medium was replaced every 3-4 days. Human 1.1B4 
cells which were a gift from Prof. Peter Flatt (3) were cultured in RPMI 1640 medium 
containing 11.1mM glucose and supplemented with 10% fetal bovine serum, 2mmol/l L-
Glutamine, 100U/ml penicillin and 100µg/ml streptomycin.1.1B4 cells were sub-cultured upon 
reaching 80% confluence and both cell lines were maintained at 370C, 100% humidity and 5% 
CO2. All cells were mycoplasma negative. 
Mutagenesis 
A pCMV6 vector containing the SIV isoform of the human CXADR gene with a Myc-DDK tag 
was purchased (ORIGENE Rockville, MD, USA).The Q5R site directed mutagenesis kit was 
used according to the manufacturer’s instruction (New England Biolabs, Hitchin, UK) to 
produce truncated variants of the protein encoded by the cDNA. Primers were synthesized to 
generate the SIV isoform without a Myc-DDK tag (F: 
GTCTATAGTATAGCGTACGCGGCC; R: CCATCCTTGCTCTGTGCT) or without the 
final three amino acids of the isoform (F: GACCAAGGATTAGTCTATAGTAACG; R: 
TGTGCTGGAATCATCACAG). All variants were fully sequenced to confirm the success of 
mutagenesis (Source Bioscience, Nottingham, UK). 
 
Western blotting 
Cells were collected and lysed in buffer (20mmol/l Tris, 150mmol/l Nacl, 1mM EDTA and 1% 
Triton-X including protease and phosphatase inhibitors (Sigma, Poole, UK)) on ice for 10mins. 
Protein lysates was separated from insoluble fraction by centrifugation at 5000rpm for 10mins 
at 40C. Total protein was estimated with the Pierce TM (BCA) Protein Assay (Thermofisher 
Scientific, UK) and absorbance was measured at 562nm with a PHERAstar (BMG Labtech). 
Equal amount of proteins (20-50ug) were adjusted with 25% of 4x lithium dodecyl sulphate 
(LDS) loading buffer and 10% β-mercaptoethanol prior to denaturing at 70oC for 10mins. 
Protein samples were loaded onto a pre-cast 12% Bis-Tris poly-acrylamide gel (Invitrogen) 
and electrophoresis was carried out using XCell Sure Lock (Invitrogen) at 120V in 20x MOPS 
SDS running buffer (Invitrogen) for 1hr. Proteins were electro-transferred onto a methanol 
permeabilized polyvinylidene difluoride (PVDF) membrane using XCell II Blot Module 
(Invitogen, UK) containing transfer buffer (Glycine, Tris, Methanol, ddH20) at 30V for 2hrs. 
Membranes were blocked in 5% skimmed milk (Sigma) in Tris buffered saline with 0.05% 
Tween 20 (TBST) buffer at room temperature for 1hr. Primary antibodies; anti-CAR-CT 
(1:1000, ab100811, Abcam), anti-CAR-ECD (1:500, ab180761, Abcam), β-actin (1:10000, 
A5441, Sigma), anti-PICK1 (1:1000, Abcam ab133773) or GAPDH (1:10000, 60004-1-Ig, 
Proteintech) were diluted in 5% milk/ TBST and membranes probed overnight at 40C, with the 
exception of β-actin and GAPDH (2hrs at room temperature). The membrane was washed 3x 
with TBST and probed with a secondary antibody raised against mouse or rabbit conjugated to 
Alkaline phosphatase (A3562, A3687, Sigma) or Goat anti-rabbit IgG (H+L) highly crossed 
absorbed, Alexafluor plus 680 (#A327-34, Thermofisher)  in 1% milk/ TBST for 1hr at room 
temperature. Finally, the membrane was washed 3x with TBST and bands were visualised with 
a CDP-Star Chemiluminescent substrate (Sigma, C0712) using either a Li-COR C-Digit or 
Odyssey CLX (Li-COR Biosciences, UK)  
 
Flow cytometry 
Cells were trypsinised and re-suspended in FACS buffer (PBS, 2% FBS). For intracellular 
staining, cells were fixed with 4% paraformaldehyde, washed twice with FACS buffer and 
incubated with either anti-CAR CT or anti-CAR-RmCB-PE (FCMAB418PE, Merck Millipore) 
or negative control antibodies. Rabbit Isotype IgG (I-1000 Vector laboratories) or Mouse 
IgG1k (FCMAB230P, Merck) in 0.3% saponin at 40C for 45mins. Cells were then washed in 
0.03% saponin in FACS buffer and then analysed immediately on a Flow cytometer (BD 
Accuri TM C6 Plus) or if they were not directly conjugated to a fluorochrome, they were 
incubated with secondary antibody (Alexa-488) for 30mins prior to analysis. For extracellular 
staining, cells were incubated with either CAR-CT or CAR-Rmcb-PE in FACS buffer at room 
temperature for 45mins. Cells were then washed in FACS buffer and analysed or incubated 
with secondary antibodies (Alexa-488) before analysis. Results were confirmed in 3 
independent experiments. 
 
Laser capture microdissection of human islets  
Laser capture microdissection (LCM) of human islets was performed on OCT frozen sections 
from pancreas of non-diabetic nPOD donors (6017, 6096; Supplementary Table 4). Briefly, 
5µm thick frozen sections were fixed in 70% ethanol for 30 seconds and then dehydrated in 
100% ethanol, xylene and then air dried for 5 minutes. An Arcturus Xt microdissection 
instrument (Thermofisher, Waltham, MA, USA) was used to capture human islets based on 
beta-cell autofluorescence. Hs-Caps (Thermofisher) were used to microdissect identified islets. 
Microdissected islets were then lysed in Arcturus Picopure kit Extraction Buffer for 30 minutes 
at 42°C and subjected to total RNA extraction using Arcturus Picopure RNA extraction kit 
following the manufacturer’s instructions (Thermofisher). 
 
 
 
Real Time RTqPCR 
Total RNA from isolated human islets was extracted using miRNeasy mini kit (Qiagen, Hilden, 
Germany). Briefly, human isolated islets were lysed in Qiazol solution and chloroform was 
added to separate DNA, RNA and proteins. The aqueous phase was then loaded on to RNA 
binding columns and eluted in 30µl of nuclease-free water. RNA quality were evaluated using 
a 2100 Bioanalyzer RNA 6000 Pico kit (Agilent Technologies, Santa Clara, CA, USA) and 
only samples with RNA Integrity Number (RIN) >5.0 were used for further analyses. 
Differential expression of alternatively spliced isoforms of the human CXADR gene were 
evaluated using custom designed TaqMan primers and probes (Thermofisher) (ESM Table 3).  
For human isolated islets (ESM Table 4), 250ng of total RNA was retro-transcribed using 
Superscript III Reverse Transcriptase kit (Thermofisher) and 10ng of the resultant cDNA were 
loaded into 2x TaqMan Universal Master Mix, 20x TaqMan gene expression assay buffer and 
nuclease-free water in a final volume of 20µl. Data were normalised using the expression of β-
Actin, GAPDH and β2-microglobulin. Reactions were performed on a Verity Thermal Cycler 
and ViiA7 Real Time PCR instruments (Thermofisher). Data were analysed and exported using 
Expression Suite software 1.1 (Thermofisher) and finally elaborated using the 2-∆Ct method.  
For LCM captured islets (ESM Table 5), 1ng of total RNA was retro-transcribed using 
Superscript III Reverse Transcriptase kit (Thermofisher). The resultant cDNA was pre-
amplified using 0.2x Tris-EDTA-diluted TaqMan assays pool (designed to amplify CXADR 
isoforms plus 3 housekeeping genes (β-Actin, GAPDH, β2-microglobulin)) and 2x Preamp 
Master Mix in a final volume of 50µl. The pre-amplification reaction was diluted in Tris-EDTA 
and 5µl of each pre-amplified cDNAs were used in a Real-Time PCR reaction in a final volume 
of 20µl. 
 
Semi-quantitative RT-PCR 
Total RNA was isolated from human islets (ESM Table 4) using RNeasy mini kits (Qiagen, 
Manchester, UK). 1µg of RNA was reverse transcribed (Promega, Madison,WI, USA) to 
synthesize cDNA. Specific primers were designed to selectively target the two CXADR 
transmembrane isoforms; CAR-SIV (F: GGAAGTTCATCACGATATCAG; 
R:AATCATCACAGGAATCGCAC), CAR-TVV (F: GGAAGTTCATCACGATATCAG; R: 
TTCCATCAGTCTTGTAAGGG). Amplified bands were excised and sequenced (Source 
Bioscience, Nottingham, UK) to confirm the isoform expression pattern. 
 
Cryo-immune EM 
For cryo-immuno-EM human samples were treated as described [24].  Briefly, human pancreas 
tissue samples (nPOD 6227, 6229 and 6330) were fixed in 4% PFA, cut into small pieces and 
immersed in 2.3 mol/l sucrose in PBS at 4°C. The samples were placed on metal stubs, frozen 
in liquid nitrogen and thin cryosections were cut and protected with sucrose/methyl cellulose 
films. For immunolabeling, the protective layer was first melted in gelatin coated dishes at 
37°C and then washed with 0.1% glycine in PBS. Then grids were incubated in PBS containing 
1% BSA with appropriate antibodies (ESM Table 2) for 45 minutes at room temperature. 
Protein A-gold labelled antibodies (diameters 5, 10 or 20nm; G. Posthuma, Utrecth) diluted in 
0.1% BSA in PBS was added onto the grids for 20 min followed by washes with 0.1% 
BSA/PBS and PBS alone. A bridging antibody was used to link the proinsulin to the 20nm gold 
particles. In double or triple labelling studies, antibodies were added sequentially with their 
respective protein-A gold conjugate, between incubations the sections were incubated briefly 
with 1% glutaraldehyde. The sections were then stained with 2% neutral uranyl acetate in water 
for 5 min and embedded for 10 min on ice with 2% methylcellulose containing 0.4% uranyl 
acetate and examined with a Jeol 1400 microscope.  
 
Quantification of CAR-SIV in Cryo-immune EM 
Quantification of CAR-CT immuno-gold labelling was performed by conventional line 
intersection counting from electron micrographs of human pancreas sections labelled with anti-
CAR-CT (4). The same array of test lines was overlaid at random positions on all micrographs.  
Intersections with membrane limited compartments (mature and immature secretory granules, 
exocrine granules, endoplasmic reticulum, mitochondria, nucleus and plasma membrane) were 
assessed and the gold particles in these specific intersections counted. 21 micrographs were 
analysed yielding a total of 841 gold particles and 1291 intersections between membrane 
compartments. Numbers of gold particles per intersection were calculated and normalized for 
the abundance of each relevant compartment. Data were then displayed as the percentage of 
CAR-SIV gold particles in each of the different compartments. For ESM Fig 6, the number of 
CAR-SIV positive granules that were also labelled with proinsulin and/ or insulin labelled gold 
particles were counted. 
 
Co-immunoprecipitation of PICK1 with CAR 
Whole cell extracts were prepared by lysing 5 x 105 EndoC-βH1 cells or human islets with 
buffer containing 50mmol/l Tris (pH 7.5); 137mmol/l NaCl; 5mmol/l EDTA; 1mmol/l EGTA; 
10µg/ml protease inhibitor (Sigma) and 10µg/ml phosphatase inhibitor cocktail 2 & 3 (Sigma, 
UK). The lysates were incubated with 3µg of anti-CAR clone RmcB or negative control mouse 
IgG (Dako; X0931) overnight at 4⁰C. Protein G Sepharose beads were then added for 4 hours 
at 4⁰C followed by three washes [first - lysis buffer; second -10% lysis buffer in TBS 
(50mmol/l Tris (pH 7.5) and 137mmol/l NaCl); Third – TBS). Proteins were eluted with 4x 
LDS and 10% β-mercaptoethanol at 70⁰C for 10min. Western blot analysis was then performed 
as described above. 
 
  
ESM Table 1: Tissue Samples, Patient Information  
Case ID Case Type Cohort Age Sex Duration 
of disease 
12425 No diabetes EADB  Neonate N/A  
8582 No diabetes EADB 1 N/A  
150/88 No diabetes EADB 3 F  
274/91 No diabetes EADB 6 M  
245/90 No diabetes EADB 6 M  
8651 No diabetes EADB 6 N/A  
12229 No diabetes EADB 10 N/A  
540/91 No diabetes EADB 11 M  
6099-06 No diabetes nPOD 14.2 M  
PM146/66 No diabetes EADB 18 F  
PAN 8 No diabetes EADB 19 N/A  
PAN 1 No diabetes EADB 22 N/A  
6160-06 No diabetes nPOD 22.1 M  
329/72 No diabetes EADB 24 M  
191/67 No diabetes EADB 25 M  
PM132/67 No diabetes EADB 46 M  
330/71 No diabetes EADB 47 M  
186/74 No diabetes EADB 55 F  
77/6/87 No diabetes EADB 57 F  
332/66 No diabetes EADB 59 M  
6098 No diabetes nPOD 17.8 M  
6153 No diabetes nPOD 15.2 M  
6027 AAb+ nPOD 18.8 M  
6167 AAb+ nPOD 37 M  
E236 T1D EADB 7 F 'Recent' 
SC41 T1D EADB 4 F 3 weeks 
11746 T1D EADB 6 M <1 week 
11713 T1D EADB 3 M 3mth 
E375 T1D EADB 11 F 1 week 
E560 T1D EADB 42 F 18mths 
6041 T1D nPOD 26.3 M 23y 
6087 T1D nPOD 17.5 M 4y 
6113 T1D nPOD 13.1 F 1.58y 
6161 T1D nPOD 19.2 F 7y 
EADB – Exeter Archival Diabetes Biobank; AAb+ - Autoantibody positive no diabetes; N/A 
– not avaliable 
 
ESM Table 2: Antibody Details and Conditions for IHC/ IF. All antisera were validated with positive and negative controls and the CAR 
antisera were further validated (ESM Fig 1)  
Primary 
Antibody 
Manufacturer 
and clone 
IHC/IF 
Antigen 
Retrieval 
Conditions and Secondary Detection System 
CAR-CT 
Abcam  ab100811 
Rabbit polyclonal 
10mmol/l 
citrate 
pH6.0 
Dako REAL Envision Detection System or Immunofluorescence staining (1/1000 for 1hr) using 
anti-rabbit IgG (H+L) Alexa Fluor-conjugated secondary antibodies (1/400 for 1hr) 
CAR-ECD 
Abcam ab180761 
Rabbit polyclonal 
10mmol/l 
citrate 
pH6.0 
Dako REAL Envision Detection or Immunofluorescence staining (1/200 for 1hr)  using anti-
rabbit IgG (H+L) Alexa Fluor-conjugated secondary antibodies (1/400 for 1hr) 
CAR 
RmcB 
Merck #05-644 
Lot # 2880699 
Mouse monoclonal 
Utilised 
for ICC 
and IP 
ICC Immunofluorescence staining (1/400 for 1hr) using anti-mouse IgG (H+L) Alexa Fluor-
conjugated secondary antibodies (1/400 for 1hr) 
Insulin 
Dako 
C#A0564 
Guinea-pig 
polyclonal 
10mmol/l 
citrate 
pH6.0 
Immunofluorescence staining (1/700 for 1hr) using anti-guinea-pig IgG (H+L) Alexa Fluor-
conjugated secondary antibodies (1/400 for 1hr) 
Glucagon 
Abcam 
C#ab82270 
Mouse monoclonal 
10mmol/l 
citrate 
pH6.0 
Immunofluorescence staining (1/2000 for 1hr) using anti-mouse IgG (H+L) Alexa Fluor-
conjugated secondary antibodies (1/400 for 1hr) 
Proinsulin 
Abcam 
ab8301 
Mouse monoclonal 
10mmol/l 
citrate 
pH6.0 
Immunofluorescence staining (1/500 for 1hr) using anti-mouse IgG (H+L) Alexa Fluor-
conjugated secondary antibodies (1/400 for 1hr) 
ZnT8 
R & D 
C#815039 
Mouse monoclonal 
10m 
mmol/l 
citrate 
pH6.0 
Immunofluorescence staining (1/63 for 1 hr) using anti-mouse IgG (H+L) Alexa Fluor-
conjugated secondary antibodies (1/400 for 1hr) 
PC1/3 
Abcam 
Ab55543 
Mouse monoclonal 
10m 
mmol/l 
citrate 
pH6.0 
Immunofluorescence staining (1/500 for 1hr) using anti-mouse IgG (H+L) Alexa Fluor-
conjugated secondary antibodies (1/400 for 1hr) 
PICK1 Santa Cruz 
10m 
mmol/l 
Citrate 
pH6.0 
Immunofluorescence staining (1/50 for 1hr) using anti-mouse IgG (H+L) Alexa Fluor-conjugated 
secondary antibodies (1/400 for 1hr) 
ESM Table 3: TaqMan Probe Sequences 
Target sequence Probe ID Taqman Probe Sequence 
CXADR EXON_2_7 AIKAMSZ ggtggatcaagtgggaagat 
CXADR EXON_3_7 AILJKY7 gtagttcttgggaagatgtg 
CXADR EXON_4_7 AIMSI5F catggttagcagggaagatg 
CXADR EXON_6_7 (CAR-SIV) AIN1HBN cgatatcagggaagatgtgc 
CXADR EXON_6_7_8 (CAR-TVV) AIPAFHV ccaacatggaaggatattcc 
 
ESM Table 4: Human islet donors, samples used for TaqMan qRT-PCR 
Sample ID Gender Age (y)  BMI (Kg/m2) 
1 M 52 34.2 
2 M 50 27.4 
3 M 55 28.0 
4 F 79 23.9 
5 M 59 26.7 
 
ESM Table 5: Donor information for LCM islet isolation 
Sample ID Gender Age (y)  BMI 
(Kg/m2) 
No. Of LCM 
captured islets 
RIN Value 
6017 F 59 24,8 52 5.1 
6096 F 16 18,8 39 7.2 
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Fig 1c.
ESM Fig. 1: Analysis of CAR antibody specificity. (a) 1.1B4 cells (see Supplementary methods) were transfected 
with either the full length CAR-SIV (upper panel) or truncated CAR-SIV (lower panel) and probed with CAR-RmcB
(red) or CAR-CT (green) antisera. Scale bar 2.5µm. The full length CAR-SIV is recognised by both the CAR-CT and 
the CAR-RmcB antisera. In contrast, the truncated CAR-SIV is only recognised by the CAR-RmcB antiserum, 
demonstrating the absolute requirement for the terminal three amino acids for CAR-CT antiserum binding. (b) Western 
blot analysis confirms that CAR-CT antisera detects only the full length CAR-SIV (40kDa) isoform in transfected 1.1B4 
cells. Cells transfected with either the truncated CAR-SIV or the Myc-tagged CAR-SIV (where the Myc-tag immediately 
at the C teminus appears to hinder antibody access) are not recognised by the CAR-CT antiserum. In contrast the 
CAR-ECD antibody that detects the ECD of CAR can recognise other CAR isoforms including CAR-TVV (40kDa) 
visible in control and empty vector cells, as well as the CAR-SIV shown in the truncated CAR-SIV, Myc-tagged CAR-
SIV and the full length CAR-SIV transfected cells.  Representative flow cytometry plots of (c) CAR-RmcB and (d) CAR-
CT antisera staining of the surface (upper panels) and intracellular expression (lower panels) on EndoC-βH1 cells. CAR-CT
Surface
Intracellular
Fig 1d.CAR-RmcB
Surface
Intracellular
CAR-CTCAR-RmcB Overlay
ESM Fig. 2: (a) RNAseq analysis of CAR isoform expression in 5 preparations of the human pancreatic beta 
cell line (ESM Table 4), EndoC-βH1 (Mean±SEM). CAR-SIV is expressed at levels 3-fold higher than CAR-TVV. 
CAR4/7 and CAR3/7 are present at low levels and CAR2/7 was undetectable. (b) Semi-quantitative RT-PCR (30 
cycles) analysis using specific CAR-SIV and CAR-TVV primers in RNA extracted from purified human islets, 
suggests in two independent islet preparations that CAR-SIV is present at a higher abundance than CAR-TVV.  
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ESM Fig 3: CAR-SIV expression is observed only in the insulin containing islets of individuals with Type 1 diabetes patients and not in insulin deficient 
islets. Representative immunofluorescence staining of the CAR-SIV isoform (CAR-CT antibody; green) insulin (light blue), glucagon (red) and DAPI (dark blue) in 
an insulin containing islet (ICI; upper panel) and insulin deficient islet (IDI; lower panel) of a donor with Type 1 diabetes. Scale bar 25µm. These results are 
representative of findings in the pancreas of 10 Type 1 diabetes donors (ESM Table 1). CAR-SIV is expressed in T1D donor islets but only in beta cells (upper 
panel). Once the beta cells have been destroyed CAR-SIV expression is lost (lower panel). CAR-SIV expression in beta cells from autoantibody positive non-
diabetic donors did not differ from that seen in autoantibody negative donors without diabetes (data not shown).  
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ESM Fig 4: CAR-SIV subcellular localisation and distribution in human 
tissue.  Immunohistochemical staining demonstrating either surface membrane 
or granular distribution of CAR-SIV in different human tissues. (a) Testes, (b) 
Bladder small cell carcinoma, (c) Brain (d) Stomach. (e) RNA-seq analysis of 
CXADR isoforms supports the expression profile  of CAR-SIV in dispersed 
human islets and various other normal human tissues. CAR-SIV is highly 
expressed in dispersed islets, brain, kidney, heart, prostate, testis and thyroid 
when compared to CAR-TVV and CAR 4/7.
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ESM Fig. 5 Manders Colocalisation Coefficient (MCC) analysis. This analysis allows us to assess how much of the proinsulin or insulin immunostaining is coincident 
with CAR-SIV and vice versa. This more detailed analysis has shown that the vast majority of CAR-SIV co-localises with insulin (MCC: 0.914±0.016) and that the same 
is also true for insulin co-localising with CAR-SIV (MCC: 0.912±0.028). This is consistent with them both being present in mature insulin secretory granules. In contrast, 
CAR-SIV does not co-localise to the same extent with proinsulin (MCC: 0.211±0.042), presumably because the majority of CAR-SIV is in the mature granules (which is 
supported by the immuno-EM quantitative analysis). In contrast, a higher proportion of proinsulin co-localises with CAR-SIV (MCC: 0.708±0.082) and this is likely to 
represent both CAR-SIV and pro-insulin in the immature granules as these emerge from the trans-Golgi. 
ESM Fig. 6 Cryo-immune EM analysis of insulin granules at different stages of maturation. Low magnification image (a) demonstrates no labelling of the pancreatic 
tissue when exposed to unconjugated gold particles and bridging antibodies.  (b-e) Immunogold labelling of insulin (5nm gold; black triangle); CAR-SIV (10nm gold; black arrow 
) and proinsulin (20nm gold; white triangle) in thin frozen sections of human pancreas tissue. The higher magnification images reveal (c) immature granules positive for 
proinsulin and CAR-SIV, (d) maturing granules positive for proinsulin, insulin and CAR-SIV and (e) mature granules positive for insulin and CAR-SIV. Scale bar: 500 nm 
a b
c d e
ESM Fig. 7 Immunoprecipitation of CAR from (a) EndoC-βH1 cells and (b) human islets also pulls down PICK1. Co-immunoprecipitation (see ESM 
Materials) was carried out with anti-CAR RmcB or anti-Mouse IgG (msIgG) as negative control. Immunoprecipitated proteins were analysed on Western blots 
probed with anti-PICK1. The membrane was then stripped and re-probed with anti-CAR CT or anti-CAR ECD. Input control (2%) was included as shown. 
Input        CAR        Input    msIgG
PICK1
CAR-CT
CAR-
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msIgG CAR
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(b) Human Islets(a) EndoC-βH1
